Caption Management’s KalVista Pharmaceuticals KALV Stock Holding History

Caption Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,907	Closed	-$1.9M	–	1813
2025 Q4	$1.9M	Sell	117,907 -23,515	-17%	-$311K	0.01%	855
2025 Q3	$1.72M	Buy	+141,422	New	+$1.95M	0.01%	903
2024 Q1	–	Sell	-165,000	Closed	-$2.02M	–	1447
2023 Q4	$2.02M	Buy	165,000 +37,134	+29%	+$338K	0.03%	615
2023 Q3	$1.23M	Buy	+127,866	New	+$1.31M	0.02%	718
2023 Q1	–	Sell	-17,139	Closed	-$116K	–	1316
2022 Q4	$116K	Buy	+17,139	New	+$91.8K	﹤0.01%	1120

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caption Management's KALV Position: Q1 2026 in Review

Caption Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 117,907 shares — an estimated $1.9M sold.

Caption Management first reported a position in KALV in Q4 2022 and held it in 5 quarters. The position peaked at $2.02M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Caption Management reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Caption Management sold 117,907 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.9M.
Caption Management first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Caption Management's KalVista Pharmaceuticals position peaked at $2.02M in Q4 2023.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.